Business
Aelis Farma Awarded a €458k Grant Under France 2030 in Nouvelle-Aquitaine to Support Development of Its Program in Obesity and Associated Metabolic Diseases
BORDEAUX, France, April 07, 2026--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral disorders involving the CB1 receptor, today announced that it has been selected under the regional component of France 2030 in Nouvelle-Aquitaine and has been awarded a grant of €458,000. This non-dilutive funding will help accelerate the Company’s research and development activities
About this update from Aelis Farma Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":252,"url":"https://media.zenfs.com/en/business-wire.com/c916c86a96f5998a36103c93415d0fe4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/G3jmLqAvZ.4CDcl0NEru0w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwNA--/https://media.zenfs.com/en/business-wire.com/c916c86a96f5998a36103c93415d0fe4","width":480,"height":252}},"lazy":false},{"type":"text","content":"This non-dilutive funding, granted under the Projets d’Avenir Innovation (PAI) scheme, strengthens Aelis Farma’s "metabolism" program and validates its innovation potential in a therapeutic area of major strategic importance.","length":235,"tagName":"p"},{"type":"text","content":"BORDEAUX, France, April 07, 2026--(BUSINESS WIRE)--Regulatory News:","length":67,"tagName":"p"},{"type":"text","content":"Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral disorders involving the CB1 receptor, today announced that it has been selected under the regional component of France 2030 in Nouvelle-Aquitaine and has been awarded a grant of €458,000. This non-dilutive funding will help accelerate the Company’s research and development activities in the field of obesity and associated metabolic diseases.","length":507,"tagName":"p"},{"type":"text","content":"This non-dilutive public support, granted under the "Projet d’Avenir Innovation" call for projects, recognizes the scientific quality of the project led by Aelis Farma, its innovative nature, and its value creation potential in a rapidly expanding therapeutic field. The program was selected as part of the regional call for projects operated on behalf of the French State and the Nouvelle-Aquitaine Region, with the support of Bpifrance.","length":448,"tagName":"p"},{"type":"text","content":"The funds awarded will be used to finance research and development work focused on the identification and characterization of new drug candidates derived from the Company’s proprietary platform of specific signaling inhibitors of the CB1 receptor (CB1-SSi). This work is intended to advance the preclinical development of new molecules for the treatment of obesity-related metabolic disorders...